ArriVent BioPharma, Inc. (AVBP) Dividend History

Company News

• ArriVent Announces a Multi-Target ADC Collaboration with Alphamab

  Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise

  GlobeNewswire Inc.
• ArriVent Appoints John Hohneker, M.D., to its Board of Directors

  NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics.

  GlobeNewswire Inc.
• ArriVent Appoints Kristine Peterson to its Board of Directors

  NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals.

  GlobeNewswire Inc.
• ArriVent BioPharma Reports Full Year 2023 Financial Results

  NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended December 31, 2023, and highlighted recent company progress.

  GlobeNewswire Inc.
• $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying

  Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform. Vera Therapeutics The Trade: Vera Therapeutics, Inc. (NASDAQ: VERA) Director Maha Katabi acquired a total of 161,290 shares an average price of $31.00. To acquire these shares, it cost around $5 million. What’s Happening: Vera Therapeutics priced its upsized public offering of ...

  Benzinga

  Featured Companies: CLF KALV VERA